SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank50
5Y CAGR-43.8%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-43.8%/yr
Long-term compound
Percentile
P50
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 13.88% |
| 2024 | 82.65% |
| 2023 | -54.68% |
| 2022 | -36.28% |
| 2021 | 104.89% |
| 2020 | 247.99% |
| 2019 | 0.00% |